Success Metrics

Clinical Success Rate
95.2%

Based on 20 completed trials

Completion Rate
95%(20/21)
Active Trials
1(4%)
Results Posted
15%(3 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
19
83%
Ph phase_2
4
17%

Phase Distribution

19

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
19(82.6%)
Phase 2Efficacy & side effects
4(17.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

95.2%

20 of 21 finished

Non-Completion Rate

4.8%

1 ended early

Currently Active

1

trials recruiting

Total Trials

23

all time

Status Distribution
Active(1)
Completed(20)
Terminated(1)
Other(1)

Detailed Status

Completed20
Active, not recruiting1
Terminated1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
1
Success Rate
95.2%
Most Advanced
Phase 2

Trials by Phase

Phase 119 (82.6%)
Phase 24 (17.4%)

Trials by Status

completed2087%
active_not_recruiting14%
terminated14%
suspended14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT05652504Phase 1

Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

Suspended
NCT06735209Phase 1

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Active Not Recruiting
NCT03503058Phase 2

Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria

Completed
NCT05604521Phase 1

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Terminated
NCT03989102Phase 2

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali

Completed
NCT04966871Phase 1

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Completed
NCT03521973Phase 2

Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children

Completed
NCT03510481Phase 1

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Completed
NCT02627456Phase 1

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali

Completed
NCT03590340Phase 1

Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea

Completed
NCT02015091Phase 1

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

Completed
NCT01988636Phase 1

Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

Completed
NCT02663700Phase 1

Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

Completed
NCT02687373Phase 1

Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

Completed
NCT03420053Phase 1

Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults

Completed
NCT03163121Phase 1

Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

Completed
NCT02704533Phase 1

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

Completed
NCT02601716Phase 2

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Completed
NCT02613520Phase 1

Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants

Completed
NCT02859350Phase 1

Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
23